临床试验研究设计终点和生物标志物药物安全性

关键字：类型：

下载页码(大于等于0,小于611)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)

warfarin,2–3 2 3

Drug resistance ABC transporters,76–77 76 77

cross-resistance,77–78 77 78

doxorubicin,78 78

exclusion criteria,76 76

imatinib,79–80 79 80

paclitaxel,78–79 78 79

tamoxifen,79 79

Dupont study,158 158

Dy schema,36–37 36 37

ECOG performance status,73–74 73 74

EDSS see Expanded Disability Status Scale Elixir Sulfanilamide,578–579 578 579

Endpoints clinical endpoint,191 191

hematological cancers event-free survival,311–313 311 313

relapse-free interval,313 313

mechanism of action and surrogate endpoints,473 473

multiple endpoints,194–195 194 195

Phase I trial,191 191

relatively objective endpoints versus relatively subjective endpoints,193–194 193 194

selection,194–195 194 195

start date,162–163 162 163

supportive care and health-related quality of life endpoint conflict,136 136

surrogate endpoint,191–192 191 192

Erlotinib,54 54

Blinding allocation concealment versus blinding,112–113 112 113

bias sources,124 124

overview,123–125 123 125

Reck schema,38–40 38 40

Blood cancers see Hematological cancers Blumenschein schema,28–30 28 30

Boceprevir,519 519

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：